Search academic texts

Information × Registration Number 0213U000726, 0110U003405 , R & D reports Title To identify of the most important factors of development of glaucoma with normal and increased intraocular pressure and on this basis to develop optimal methods for its treatment popup.stage_title Head Kluev Georgiy O., Registration Date 13-03-2013 Organization The Filatov Research Institute of Diseases and Tissue Therapy popup.description2 Research theme: Identification of the most significant factors of glaucoma with normal and increased intraocular pressure development, and on this basis to develop the optimum treatment methods Object of study: Patients with primary open-angle glaucoma. Aim: To develop the new technology of glaucoma differential treatment based on systemic and local risk factors for the development of primary open-angle glaucoma with high and normal eye pressure study (medical, laser, surgery treatment) and to improve its efficiency and prevent disability due to irreversible vision loss. Research tasks: 1. To study the most important risk factors for glaucoma and high-normal eye pressure on the systemic and local levels. 2. To conduct the analysis and comparative assessment of glaucoma normal and high eye pressure risk factors. 3. To develop the new technologies of differentiated treatment depending on getting results. 4. To develop the new ways of laser treatment combination on the eye structures in order to improve trabecular and uveoscleral ocular fluid outflow. 5. To investigate the effectiveness e of different parameters laser radiation combined effects on trabecular and uveoscleral outflow state. 6. To elaborate the arrangements for optimal laser irradiation implementation on the eye structure in order to normalize its excited hydro-and hemodynamics. Results 1. In patients with POAG the ocular blood decrease flow depending on the disease stage: in the initial stage REOGRAPHICAL coefficient (RQ) decreased by 22% (p <0.05), while developed - by 63% (p <0.05) in comparison with the norm. Correction of ocular blood flow can be revealed by bioflavanoid drug Corvitin. At the initial stage corvitin RQ influence increased by 30% (p <0.05) and reached normal values. In developed POAG coefficient increased by 55% (p <0.05) from baseline values before treatment. 2.. In patients with POAG detected the of change blood lipid profile aterohenoyi orientation depending on the stage of the disease. In the initial stage of the disease POAG the level of aterohenoyi fraction cholesterol (LDL-C) was increased by 26% (p <0.05), with advanced stage - by 102% (P <0.05) from the norm. Drug Corvitin had positive impact on lipid metabolism in patients with POAG. The decrease of LDL cholesterol in the initial stages by 32% (p <0.05) in advanced - 27% (p <0.05). 3. The elevated levels of oxidative stress in patients with glaucoma Corvitin can adjust. The content of malondialdehyde decreased by 29% (p <0.05), peroxide hemolysis decreased by 46% (p <0.05). Reduced glaucoma level stable metabolite of nitric oxide nitrite ion levels with the Corvitin treatment increased by 29.5% (p <0.05). It is possible to mark correlation between the blood supply to the eye and the concentration of nitric oxide in the blood (r = 0,68, p <0,05). 4. SLT is an effective low-impact method for glaucoma treatment. 5. After selective laser trabeculoplasty application in patients with open-angle glaucoma first, second and third phases, IOP decreased by an average of 18%, or in absolute terms - 4.53 mm Hg., the success achieved in 79% of cases. 6. Complications were absent in all SLT cases , combined with antihypertensive drug therapy SLT can stop the glaucomatous process progression and avoid invasive antiglaucomatous surgery usually accompanied by many complications. 7. Application of laser trancscleral cyclocoagulation pulsed-periodic regime exposure reduced risk of adverse complications, reduced pain, treatment can be repeated if it is necessary. 8. Microimpulse laser trancscleral cyclocoagulation can be most effective in combination with other laser glaucoma treatments. Product Description popup.authors Драгомирецька Олена Іванівна Зборовська Олександра Володимірівна Кашинцева Людмила Терентіївна Клюєв Георгій Олегович Коновалова Наталья Валерівна Лінник-Чокова Ірина Борисовна Міхейцева Ірина Миколаївна Наріцина Наталья Ільінішна Перетягін Олег Анатолійович Савко Валентин Владиславович Серебіна Тамара Михайлівна popup.nrat_date 2020-04-02 Close